Pfizer has resolved all but three of 35,000 claims over its withdrawn diabetes drug Rezulin for a total of about $750 million, 21 percent less than what it set aside for the cases, people familiar with the litigation said.
Pfizer, which is acquiring rival Wyeth for almost $64 billion, paid about $500 million to settle Rezulin cases consolidated in federal court in New York, according to court filings. The company also paid as much as $250 million to resolve state-court suits, two people familiar with the cases said. In 2004, it set aside $955 million to end Rezulin cases.
More at Bloomberg